4974.T लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 11:45):

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...

Stats
आज की मात्रा	199 600
औसत मात्रा	362 171
बाजार मूल्य	122.82B
EPS	¥0 ( 2024-02-14 )
अगली कमाई की तारीख	( ¥14.90 ) 2024-05-10
Last Dividend	¥42.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	78.04
ATR14	¥0.555 (0.05%)

मात्रा सहसंबंध

लंबा: -0.03 (neutral)

छोटा: 0.00 (neutral)

Signal:(45.092) Neutral

Takara Bio Inc. सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Takara Bio Inc. सहसंबंध - मुद्रा/वस्त्र

-0.15
( neutral )

0.03
( neutral )

-0.51
( weak negative )

0.01
( neutral )

-0.12
( neutral )

-0.48
( neutral )

Takara Bio Inc. वित्तीय

Annual	2022
राजस्व:	¥78.14B
सकल लाभ:	¥44.77B (57.29 %)
EPS:	¥132.97

FY	2022
राजस्व:	¥78.14B
सकल लाभ:	¥44.77B (57.29 %)
EPS:	¥132.97

FY	2022
राजस्व:	¥67.70B
सकल लाभ:	¥49.21B (72.69 %)
EPS:	¥164.84

FY	2021
राजस्व:	¥46.09B
सकल लाभ:	¥31.87B (69.16 %)
EPS:	¥79.29

Financial Reports:

No articles found.

Takara Bio Inc. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥0 (N/A)	¥0 (N/A)	¥42.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

Takara Bio Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.16 - good (81.59%) | Divividend Growth Potential Score: 6.06 - Stable (21.23%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.000	2012-03-28
Last Dividend	¥42.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	13	--
Total Paid Out	¥114.10	--
Avg. Dividend % Per Year	0.00%	--
Score	2.76	--
Div. Sustainability Score	8.16
Div.Growth Potential Score	6.06
Div. Directional Score	7.11	--

Next Divdend (Est)
(2024-12-31)

¥0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

2.76

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8117.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7458.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6676.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
6005.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4709.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
3940.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3166.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2139.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
9658.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8600.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0330	1.500	9.34	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0128	1.200	9.57	10.00	[0 - 0.3]
returnOnEquityTTM	0.0141	1.500	-0.954	-1.431	[0.1 - 1]
payoutRatioTTM	3.21	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	7.45	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.46	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.25	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	61.42	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	200.29	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	81.73	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.553	1.000	4.11	4.11	[0.2 - 0.8]
operatingProfitMarginTTM	0.0309	1.000	-1.382	-1.382	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.387	0.800	-0.751	-0.601	[0.5 - 2]
Total Score				8.16

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	78.72	1.000	2.15	0	[1 - 100]
returnOnEquityTTM	0.0141	2.50	-0.613	-1.431	[0.1 - 1.5]
freeCashFlowPerShareTTM	81.73	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.655	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	200.29	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	3.21	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	54.51	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.506	1.000	10.00	0	[0.1 - 0.5]
Total Score				6.06

Takara Bio Inc.

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

के लिए वास्तविक समय के अद्यतन Takara Bio Inc. [4974.T]

Upcoming Earnings Alert

Takara Bio Inc. Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for JPX

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)